Play-by-play: How Sanofi jacked up its offer twice to seal the $1.9B deal for Kadmonnews2021-09-22T15:43:20+00:00September 22nd, 2021|Fierce Pharma|
With $68.2M investment from India’s Serum, Oxford Biomedica set to add capacity and 120 jobs at its ‘Oxbox’ sitenews2021-09-22T15:06:45+00:00September 22nd, 2021|Fierce Pharma|
Novartis reshuffling doesn’t portend a pullback from gene therapy, company saysnews2021-09-22T14:42:45+00:00September 22nd, 2021|Fierce Pharma|
Struggling with Alzheimer’s launch, Biogen couldn’t present ‘clear case for growth’ outside of Aduhelm: analystnews2021-09-22T14:08:59+00:00September 22nd, 2021|Fierce Pharma|
Pfizer, Moderna, AZ and other COVID vaccine companies face urgent calls to ramp up access around the worldnews2021-09-22T14:01:03+00:00September 22nd, 2021|Fierce Pharma|
Incyte’s Jakafi sister med clears FDA for atopic dermatitis, but safety warning a heavy cross to bearnews2021-09-22T11:42:35+00:00September 22nd, 2021|Fierce Pharma|
AstraZeneca lays out $360M for ‘next-gen’ manufacturing plant in Dublinnews2021-09-21T15:28:34+00:00September 21st, 2021|Fierce Pharma|
Verrica’s lead drug VP-102 rejected by FDA thanks to issues at contract manufacturernews2021-09-21T14:26:01+00:00September 21st, 2021|Fierce Pharma|
Seagen, Genmab gun for Merck’s Keytruda in cervical cancer with accelerated FDA nod for ADC therapy Tivdaknews2021-09-21T14:07:05+00:00September 21st, 2021|Fierce Pharma|
Johnson & Johnson trots out two-dose COVID vaccine data as it builds case for boostersnews2021-09-21T13:52:11+00:00September 21st, 2021|Fierce Pharma|
